etalocib

Etalocib is a potent, orally active small molecule of the biphenylphenol class that acts primarily as a selective leukotriene B4 receptor (LTB4R) antagonist. It also functions as an agonist of peroxisome proliferator-activated receptor gamma (PPARγ) and inhibits arachidonate 5-lipoxygenase (5-LOX). Etalocib was developed for its anti-inflammatory and antineoplastic properties, efficiently blocking neutrophil activation and inflammation, while inducing cell cycle arrest and apoptosis in tumor cells. It was investigated for the treatment of various cancers—including non-small cell lung cancer and pancreatic cancer—as well as inflammatory diseases such as asthma, psoriasis, and ulcerative colitis. Clinical development was discontinued due to lack of efficacy[1][3][4][5][6].

Other names

etalocib sodium